Last Price
0.50
Today's Change
+0.279 (126.24%)
Day's Change
0.44 - 0.879
Trading Volume
237,184,790
Overview
Market Cap
5 Million
Shares Outstanding
10 Million
Avg Volume
687,829
Avg Price (50 Days)
0.24
Avg Price (200 Days)
0.74
PE Ratio
-0.09
EPS
-5.28
Earnings Announcement
07-Aug-2023
Previous Close
0.22
Open
0.79
Day's Range
0.4401 - 0.8786
Year Range
0.197 - 6.78
Trading Volume
238,325,660
Price Change Highlight
1 Day Change
126.04%
5 Day Change
126.24%
1 Month Change
120.85%
3 Month Change
107.56%
6 Month Change
-43.36%
Ytd Change
-90.18%
1 Year Change
-89.36%
3 Year Change
-99.70%
5 Year Change
-99.57%
10 Year Change
-99.57%
Max Change
-99.57%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Latest Videos
Apps
Top Articles
1
CEO Morning Brief
US New-home Sales Rebound in November After Storm-stricken Month
2
CEO Morning Brief
Orders for US Business Equipment Rise by Most in Over a Year
3
CEO Morning Brief
4
CEO Morning Brief
Google to Fight Japan’s Claims That It Hobbles Rivals in Search
5
CEO Morning Brief
Musk Makes ‘overstaffed’ US Fed Target in Quest for Efficiency
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
